No significant differences in demographic characteristics were observed between the CY+ and CY− groups, specifically in regard to the following parameters: age; sex; any of the assessed tumor attributes, including tumor diameter, histopathological type, depth of invasion, lymph node metastasis, invasion of the anterior pancreatic capsule or retroperitoneal tissue, portal vein invasion, arterial invasion, perineural invasion, lymph vessel invasion, or vascular invasion; serum levels of CEA or CA19-9; or pre-/postoperative treatment (Table 2). The gene discussed is CEACAM5; the disease is neoplasm.